Wintzer-Wehekind J, Horlick E, Ibrahim R, et al. - In this prespecified analysis of a randomized clinical trial involving 171 patients (27 [15.8%] with new-onset migraine attacks), researchers evaluated the incidence of migraine attacks at 6- and 12-month follow-up after transcatheter atrial septal defect (ASD) closure. Study participants were randomized (1:1) to receive dual antiplatelet therapy (aspirin plus clopidogrel; n = 84) vs single antiplatelet therapy (aspirin plus placebo; n = 87) for 3 months following transcatheter ASD closure. In most patients, new-onset migraine attacks following ASD closure improved or resolved spontaneously within 6 to 12 months. After 3 months of clopidogrel cessation, no major rebound effect was observed. Such findings indicate a low rate of migraine events beyond 3 months after transcatheter ASD closure and support early discontinuation of clopidogrel therapy if administered.